Poised epigenetic states and acquired drug resistance in cancer

Brown, Robert; Curry, Edward; Magnani, Luca; Wilhelm-Benartzi, Charlotte S.; Borley, Jane

doi:10.1038/nrc3819

Cited by 303Epigenetics and DNA MethylationChromatin Remodeling and CancerCancer Cells and Metastasis

Poised epigenetic states and acquired drug resistance in cancer

Brown, Robert, Curry, Edward, Magnani, Luca, Wilhelm-Benartzi, Charlotte S., Borley, Jane·2014·Nature Reviews Cancer

DOI 10.1038/nrc3819

Open this paper in CoChat — free account

Abstract

Epigenetic events, which are somatically inherited through cell division, are potential drivers of acquired drug resistance in cancer. The high rate of epigenetic change in tumours generates diversity in gene expression patterns that can rapidly evolve through drug selection during treatment, leading to the development of acquired resistance. This will potentially confound stratified chemotherapy decisions that are solely based on mutation biomarkers. Poised epigenetic states in tumour cells may drive multistep epigenetic fixation of gene expression during the acquisition of drug resistance, which has implications for clinical strategies to prevent the emergence of drug resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc3819

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The majority of patients who respond well to initial targeted cancer therapy develop resistance.
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [59]

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,949 · see citing works
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361 · see citing works
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · see citing works
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · see citing works
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · see citing works
Tumour heterogeneity and cancer cell plasticity
Meacham, C., & Morrison, S. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,350 · see citing works
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993 · see citing works
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
Sternberg, S. H., Redding, S., Jínek, M., Greene, E. C., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13011 · Cited by 1,775 · see citing works
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475 · see citing works
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443 · see citing works
Chromatin signatures of pluripotent cell lines
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H. F., John, R. M., Gouti, M., Casanova, M., Warnes, G., Merkenschlager, M., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1403 · Cited by 1,357 · see citing works
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacıoğlu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,282 · see citing works
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226 · see citing works
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · see citing works
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,155 · see citing works
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143 · see citing works
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., Brooks, M. W., Reinhardt, F., Su, Y., Polyák, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102454108 · Cited by 1,137 · see citing works
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136 · see citing works
A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130 · see citing works
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915 · see citing works
Unravelling cancer stem cell potential
Beck, B., & Blanpain, C. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3597 · Cited by 895 · see citing works
Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G. W., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 873 · see citing works
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · see citing works
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806 · see citing works
Genetic variegation of clonal architecture and propagating cells in leukaemia
Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S., Kempski, H. M., Moorman, A. V., Titley, I., Swansbury, J. G., et al. (2010) · Nature · doi:10.1038/nature09650 · Cited by 803 · see citing works
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794 · see citing works
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 780 · see citing works
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · see citing works
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 623 · see citing works
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Pujade-Lauraine, É., Wagner, U. A. G., Aavall-Lundqvist, E., Gebski, V., Heywood, M. S., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 573 · see citing works
Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG Islands
O’Hagan, H. M., Wang, W., Sen, S., Shields, C. E. D., Lee, S. S., Zhang, Y. W., Clements, E. G., Cai, Y., Neste, L. V., Easwaran, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.012 · Cited by 569 · see citing works
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H. X., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 550 · see citing works
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 515 · see citing works
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486 · see citing works
Self-citation
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Konze, K. D., Ma, A., Li, F., Baršytė-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 450 · see citing works
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391 · see citing works
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390 · see citing works
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387 · see citing works
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 386 · see citing works
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003346 · Cited by 374 · see citing works
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D. E., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 369 · see citing works
Investigating stem cells in human colon by using methylation patterns
Yatabe, Y., Tavaré, S., & Shibata, D. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191225998 · Cited by 368 · see citing works
Locus-specific editing of histone modifications at endogenous enhancers
Mendenhall, E. M., Williamson, K. E., Reyon, D., Zou, J., Ram, O., Joung, J. K., & Bernstein, B. (2013) · Nature Biotechnology · doi:10.1038/nbt.2701 · Cited by 362 · see citing works
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
Strathdee, G. R., Mackean, M., Illand, M., & Brown, R. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350 · see citing works
Self-citation
Strategies for the management of adverse events associated with mTOR inhibitors
Kaplan, B. E., Qazi, Y. A., & Wellen, J. R. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.002 · Cited by 322 · see citing works
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 298 · see citing works
A DNA hypermethylation module for the stem/progenitor cell signature of cancerPreprint
Easwaran, H., Johnstone, S. E., Neste, L. V., Ohm, J. E., Mosbruger, T., Wang, Q., Aryee, M. J., Joyce, P., Ahuja, N., Weisenberger, D., et al. (2012) · Genome Research · doi:10.1101/gr.131169.111 · Cited by 293 · see citing works
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
Zeller, C., Dai, W., Steele, N. L., Siddiq, A., Walley, A. J., Wilhelm-Benartzi, C. S., Rizzo, S., van der Zee, A. G. J., Plumb, J. A., & Brown, R. E. (2012) · Oncogene · doi:10.1038/onc.2011.611 · Cited by 285 · see citing works
Self-citation
Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
Thomas, A., Rouby, S. E., Reed, J. C., Krajewski, S., Silber, R.-E., Potmĕsil, M., & Newcomb, E. (1996) · PubMed · Cited by 265 · see citing works
The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., & Brown, R. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262 · see citing works
Self-citation
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2795 · Cited by 262 · see citing works
Epigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236 · see citing works
Self-citation
Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors
Appleton, K., MacKay, H. J., Judson, I. R., Plumb, J. A., McCormick, C., Strathdee, G. R., Lee, C., Barrett, S., Reade, S., Jadayel, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8688 · Cited by 228 · see citing works
Self-citation
Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos‐Silva, A., Liber, D., Luk, L., Titley, I., Carden, C. P., Box, G., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0788 · Cited by 204 · see citing works
Self-citation
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer
Fu, S., Hu, W., Iyer, R. B., Kavanagh, J. J., Coleman, R. L., Levenback, C. F., Sood, A. K., Wolf, J. K., Gershenson, D. M., Markman, M. M., et al. (2010) · Cancer · doi:10.1002/cncr.25701 · Cited by 183 · see citing works
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
Magnani, L., Stoeck, A., Zhang, X., Lánczky, A., Mirabella, A., Wang, T., Győrffy, B., & Lupien, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219992110 · Cited by 181 · see citing works
Self-citation
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
Senisterra, G. A., Wu, H. Y., Allali‐Hassani, A., Wasney, G. A., Baršytė-Lovejoy, D., Dombrovski, L., Dong, A., Nguyen, K. T., Smil, D. V., Bolshan, Y., et al. (2012) · Biochemical Journal · doi:10.1042/bj20121280 · Cited by 165 · see citing works
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Garapaty, S., Nasveschuk, C. G., Gagnon, A., Chan, E. Y., Sandy, P., Busby, J., Balasubramanian, S., Campbell, R., Zhao, F., Bergeron, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.013 · Cited by 154 · see citing works
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts
Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151 · see citing works
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
Chen, Q., van der Sluis, P. C., Boulware, D. C., Hazlehurst, L., & Dalton, W. S. (2005) · Blood · doi:10.1182/blood-2004-11-4286 · Cited by 143 · see citing works
O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Brandes, A. A., Franceschi, E., Tosoni, A., Bartolini, S., Bacci, A., Agati, R., Ghimenton, C., Turazzi, S., Talacchi, A., Škrap, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop050 · Cited by 141 · see citing works
Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts
Topp, M. D., Hartley, L., Cook, M., Heong, V. Y. M., Boehm, E., McShane, L., Pyman, J. M., McNally, O., Ananda, S. S., Harrell, M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.008 · Cited by 137 · see citing works
Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells
Li, H., Cai, Q. K., Godwin, A. K., & Zhang, R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0398 · Cited by 131 · see citing works
Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers
Chang, X., Monitto, C. L., Demokan, S., Kim, M. S., Chang, S. S., Zhong, X., Califano, J. A., & Sidransky, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3427 · Cited by 129 · see citing works
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
Glasspool, R. M., Brown, R. E., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.116 · Cited by 125 · see citing works
Self-citation
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117 · see citing works
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma
Christmann, M., Nagel, G., Horn, S., Krahn, U., Wiewrodt, D., Sommer, C., & Kaina, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25229 · Cited by 117 · see citing works
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 116 · see citing works
The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer
Zhuang, J. J., Jones, A., Lee, S., Ng, E., Fiegl, H., Zikán, M., Cibula, D., Sargent, A., Salvesen, H. B., Jacobs, I. J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002517 · Cited by 116 · see citing works
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer
Zhang, Y., Zheng, Y., Wang, J., Lu, X., Wang, Z., Chen, L., Guan, X., & Tong, J. (2014) · Epigenetics · doi:10.4161/epi.28601 · Cited by 112 · see citing works
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
Dizon, D. S., Blessing, J. A., Penson, R. T., Drake, R. D., Walker, J. L., Johnston, C. M., DiSilvestro, P., & Fader, A. N. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.019 · Cited by 102 · see citing works
Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
Parkinson, J., Wheeler, H., Clarkson, A., McKenzie, C. A., Biggs, M. T., Little, N., Cook, R., Messina, M., Robinson, B. G., & McDonald, K. L. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9486-0 · Cited by 91 · see citing works
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
Chapman‐Rothe, N., Curry, E. W., Zeller, C., Liber, D., Stronach, E. A., Gabra, H., Ghaem‐Maghami, S., & Brown, R. E. (2012) · Oncogene · doi:10.1038/onc.2012.477 · Cited by 90 · see citing works
Self-citation
Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer
Jansen, M. P. H. M., Knijnenburg, T., Reijm, E. A., Simón, I., Kerkhoven, R. M., Droog, M., Velds, A., Laere, S. V., Dirix, L. Y., Alexi, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0704 · Cited by 86 · see citing works
Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
Dizon, D. S., Damstrup, L., Finkler, N. J., Lassen, U., Celano, P., Glasspool, R. M., Crowley, E. M., Lichenstein, H. S., Knoblach, P., & Penson, R. T. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31825736fd · Cited by 86 · see citing works
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 67 · see citing works
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Falchook, G. S., Fu, S., Naing, A., Hong, D. S., Hu, W., Moulder, S. L., Wheler, J. J., Sood, A. K., Bustinza-Linares, E., Parkhurst, K. L., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0003-3 · Cited by 65 · see citing works
The evolution of the unstable cancer genome
Burrell, R. A., & Swanton, C. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.011 · Cited by 64 · see citing works
Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
Fan, H., Lu, X.-C., Wang, X., Liu, Y., Guo, B., Zhang, Y., Zhang, W., Nie, J., Feng, K., Chen, M., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/371087 · Cited by 64 · see citing works
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer
Sonpavde, G., Aparicio, A. M., Zhan, F., North, B., Delaune, R., Garbo, L. E., Rousey, S. R., Weinstein, R. E., Xiao, L., Boehm, K. A., et al. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.09.015 · Cited by 62 · see citing works
The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
Park, C., Kim, J., Kim, J. Y., Song, S. W., Kim, J. W., Choi, S. H., Kim, T. M., Lee, S., Kim, I. H., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12253 · Cited by 59 · see citing works
Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
Zeller, C., & Brown, R. E. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375759 · Cited by 54 · see citing works
Self-citation
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma
Jung (2010) · Oncology Reports · doi:10.3892/or_00000760 · Cited by 52 · see citing works
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
Bauer, S., Hilger, R. A., Mühlenberg, T., Grabellus, F., Nagarajah, J., Hoiczyk, M., Reichardt, A., Ahrens, M., Reichardt, P., Grünewald, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.826 · Cited by 51 · see citing works
A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
Watanabe, Y., Ueda, H., Etoh, T., Koike, E., Fujinami, N., Mitsuhashi, A., & Hoshiai, H. (2007) · PubMed · Cited by 49 · see citing works
Current Limitations And Future Opportunities For Epigenetic Therapies
Cherblanc, F., Chapman‐Rothe, N., Brown, R. E., & Fuchter, M. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.7 · Cited by 44 · see citing works
Self-citation
In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene.
Shen, D. W., PASTAN, I., & Gottesman, M. M. (1988) · PubMed · Cited by 29 · see citing works
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance
Monsma, D. J., Cherba, D., Richardson, P. J., Vance, S. M., Rangarajan, S. V., Dylewski, D., Eugster, E., Scott, S. B., Beuschel, N. L., Davidson, P. J., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25039 · Cited by 23 · see citing works
Approaches to Target the Genome and Its Epigenome in Cancer
Chapman‐Rothe, N., & Brown, R. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.105 · Cited by 8 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,896 · see citing works
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00308-y · Cited by 977 · see citing works
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 807 · see citing works
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyák, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3971 · Cited by 558 · see citing works
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 376 · see citing works
Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells
Vassalli, G. (2019) · Stem Cells International · doi:10.1155/2019/3904645 · Cited by 300 · see citing works
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gómez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I. P., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 239 · see citing works
Mechanisms of Resistance to Antibody–Drug Conjugates
Loganzo, F., Sung, M. S., & Gerber, H. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0408 · Cited by 237 · see citing works
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 218 · see citing works
Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 213 · see citing works
Long non-coding RNAs regulate drug resistance in cancer
Liu, K., Gao, L., Ma, X., Huang, J., Chen, J., Zeng, L., Ashby, C. R., Zou, C., & Chen, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01162-0 · Cited by 203 · see citing works
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 201 · see citing works
The role of polyphenols in overcoming cancer drug resistance: a comprehensive review
Dana, P. M., Sadoughi, F., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00301-9 · Cited by 186 · see citing works
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182 · see citing works
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 179 · see citing works
Single-cell RNA sequencing reveals intrinsic and extrinsic regulatory heterogeneity in yeast responding to stress
Gasch, A. P., Yu, F. B., Hose, J., Escalante, L. E., Place, M., Bacher, R. L., Kanbar, J. N., Ciobanu, D., Sandor, L., Grigoriev, I. V., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2004050 · Cited by 159 · see citing works
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
Shen, H., Liu, B., Xu, J., Zhang, B., Wang, Y., Shi, L., & Cai, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01145-8 · Cited by 166 · see citing works
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo
Yan, J., Chen, J., Zhang, S., Hu, J., Huang, L., & Li, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00021 · Cited by 165 · see citing works
RNA therapy: Are we using the right molecules?
Yu, A., Jian, C., Yu, A. H., & Tu, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 162 · see citing works
Epigenetics of dementia: understanding the disease as a transformation rather than a state
Maloney, B., & Lahiri, D. K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00065-x · Cited by 154 · see citing works
Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer
Hesham, H. M., Lasheen, D. S., & Abouzid, K. A. M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21505 · Cited by 148 · see citing works
Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 144 · see citing works
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 146 · see citing works
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Y., Zhu, H., Lee, J., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., Yin, X., Palozola, K. C., Gardini, A., Showe, L. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0854 · Cited by 142 · see citing works
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 141 · see citing works
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 130 · see citing works
CellBox: Interpretable Machine Learning for Perturbation Biology with Application to the Design of Cancer Combination Therapy
Yuan, B., Shen, C., Luna, A., Korkut, A., Marks, D. S., Ingraham, J., & Sander, C. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.013 · Cited by 128 · see citing works
Fibrin Stiffness Mediates Dormancy of Tumor-Repopulating Cells via a Cdc42-Driven Tet2 Epigenetic Program
Liu, Y., Lv, J., Liang, X., Yin, X., Zhang, L., Chen, D., Jin, X., Fiskesund, R., Tang, K., Ma, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3719 · Cited by 120 · see citing works
Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters
Němcová‐Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., & Kovár̆, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.020 · Cited by 116 · see citing works
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 121 · see citing works
Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment
Wong, J. J. L., Gao, D., Nguyen, T. V., Kwok, C., van Geldermalsen, M., Middleton, R., Pinello, N., Thoeng, A., Nagarajah, R., Holst, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15134 · Cited by 110 · see citing works
Two-in-One Chemogene Assembled from Drug-Integrated Antisense Oligonucleotides To Reverse Chemoresistance
Mou, Q., Ma, Y., Ding, F., Gao, X., Yan, D., Zhu, X., & Zhang, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13875 · Cited by 109 · see citing works
Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation
Chisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 96 · see citing works
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
Guo, L., Lee, Y., Zhou, Y., & Huang, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 96 · see citing works
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
wang, L., Li, H., Ren, Y., Zou, S., Fang, W., Jiang, X., Li, J., Li, M., Liu, X., Yuan, X., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.328 · Cited by 93 · see citing works
Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics
Fedyuk, V., Erez, N., Furth, N., Beresh, O., Andreishcheva, E. N., Shinde, A., Jones, D. R., Zakai, B. B., Mavor, Y., Peretz, T., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01447-3 · Cited by 92 · see citing works
Micrornas as Pharmacogenomic Biomarkers for Drug Efficacy and Drug Safety Assessment
Koturbash, I., Tolleson, W. H., Guo, L., Yu, D., Chen, S., Hong, H., Mattes, W. B., & Ning, B. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.89 · Cited by 88 · see citing works
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Curry, E. W., Green, I., Chapman‐Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0118-9 · Cited by 86 · see citing works
Self-citation
Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
Krushkal, J., Silvers, T. R., Reinhold, W. C., Sonkin, D., Vural, S., Connelly, J., Varma, S., Meltzer, P. S., Kunkel, M. W., Rapisarda, A., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00876-8 · Cited by 84 · see citing works
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
Li, G., Qu, Q., Qi, T.-T., Teng, X.-Q., Zhu, H., Wang, J., Lu, Q., & Qu, J. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01974-y · Cited by 86 · see citing works
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Venkadakrishnan, V. B., Presser, A. G., Singh, R., Booker, M. A., Traphagen, N. A., Weng, K., Voss, N. C. E., Mahadevan, N. R., Mizuno, K., Puca, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51156-5 · Cited by 84 · see citing works
The evolutionary theory of cancer: challenges and potential solutions
Laplane, L., & Maley, C. C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00734-2 · Cited by 85 · see citing works
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 80 · see citing works
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 80 · see citing works
Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy
Pouchol, C., Clairambault, J., Lorz, A., & Trélat, E. (2017) · Journal de Mathématiques Pures et Appliquées · doi:10.1016/j.matpur.2017.10.007 · Cited by 75 · see citing works
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Adelaiye-Ogala, R. M., Budka, J. A., Damayanti, N. P., Arrington, J. V., Ferris, M. W., Hsu, C.-C., Chintala, S., Orillion, A. R., Miles, K. M., Shen, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0899 · Cited by 75 · see citing works
WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation
Liu, H., Chen, W., Liang, C., Chen, B. W., Zhi, X., Zhang, S., Zheng, X., Bai, X., & Liang, T. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.001 · Cited by 74 · see citing works
Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides
Chang, Z., Billmyre, R. B., Lee, S. C., & Heitman, J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007957 · Cited by 72 · see citing works
Isorhamnetin suppresses PANC-1 pancreatic cancer cell proliferation through S phase arrest
Wang, J., Quan, Q., Ji, R., Guo, X., Zhang, J., Li, X., & Liu, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.105 · Cited by 72 · see citing works
Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer
Lin, F., Wen, D., Wang, X., & Mahato, R. I. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.036 · Cited by 72 · see citing works
Ovarian cancer stem cells: What progress have we made?
Al-Alem, L., Pandya, U. M., Baker, A. T., Bellio, C., Zarrella, B., Clark, J., DiGloria, C. M., & Rueda, B. R. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.12.010 · Cited by 71 · see citing works
MicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 67 · see citing works
Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
Kim, J., Shim, M. K., Yang, S., Moon, Y., Song, S., Choi, J., Kim, J., & Kim, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.065 · Cited by 70 · see citing works
PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
Wang, J., Wang, C., Xu, P., Li, X., Lu, Y., Jin, D., Yin, X., Jiang, H., Huang, J. L., Xiong, H., et al. (2021) · Theranostics · doi:10.7150/thno.42345 · Cited by 70 · see citing works
EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma
Li, Y., He, Q., Wen, X., Hong, X.-H., Yang, X., Tang, X.-R., Zhang, P., Lei, Y., Sun, Y. H., Zhang, J., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0208-2 · Cited by 70 · see citing works
Lessons from the Crypt: HMGA1—Amping up Wnt for Stem Cells and Tumor Progression
Resar, L. M. S., Chia, L., & Xian, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3045 · Cited by 69 · see citing works
Fibronectin‐1 modulated by the long noncoding RNA OIP5‐AS1/miR‐200b‐3p axis contributes to doxorubicin resistance of osteosarcoma cells
Zhu, K., Zhang, C., Xiao‐Long, M., & Zhang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27435 · Cited by 69 · see citing works
Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes
Moody, R., Lo, M., Meagher, J. L., Lin, C.-C. A., Stevers, N. O., Tinsley, S. L., Jung, I., Matvekas, A., Stuckey, J. A., & Sun, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811463 · Cited by 68 · see citing works
Harnessing Tumor Evolution to Circumvent Resistance
McNamara, K. L., & Curtis, C. N. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.007 · Cited by 66 · see citing works
Determinants of nutrient limitation in cancer
Sullivan, M. R., & Heiden, M. G. V. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1611733 · Cited by 65 · see citing works
Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
Feldheim, J., Kessler, A. F., Monoranu, C. M., Ernestus, R., Löhr, M., & Hagemann, C. (2019) · Cancers · doi:10.3390/cancers11121837 · Cited by 67 · see citing works
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies
Pisanic, T. R., Athamanolap, P., Poh, W., Chen, C., Hulbert, A., Brock, M. V., Herman, J. G., & Wang, T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv795 · Cited by 67 · see citing works
Circulating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 65 · see citing works
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer
Borley, J., & Brown, R. E. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1043140 · Cited by 65 · see citing works
Self-citation
Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3
He, C.-S., Liu, Y.-C., Xu, Z., Dai, P.-C., Chen, X., & Jin, D.-H. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453175 · Cited by 65 · see citing works
Understanding the role of phenotypic switching in cancer drug resistance
Gunnarsson, E. B., De, S., Leder, K., & Foo, J. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110162 · Cited by 63 · see citing works
Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer
Bhat, S., Kabekkodu, S. P., Noronha, A., & Satyamoorthy, K. (2015) · Biochimie · doi:10.1016/j.biochi.2015.12.018 · Cited by 66 · see citing works
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Bonito, N. A., Borley, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., & Brown, R. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1669 · Cited by 64 · see citing works
Self-citation
Oxygen nanobubbles revert hypoxia by methylation programming
Bhandari, P. N., Cui, Y., Elzey, B. D., Goergen, C. J., Long, C. M., & Irudayaraj, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08988-7 · Cited by 64 · see citing works
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 62 · see citing works
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61 · see citing works
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination
Sun, X., Bao, J., You, Z., Chen, X., & Cui, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11745 · Cited by 59 · see citing works
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61 · see citing works
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Ming, H., Li, B., Jiang, J., Qin, S., Nice, E. C., He, W., Lang, T., & Huang, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01398-5 · Cited by 60 · see citing works
Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas
Sun, X., Liu, X., Xia, M., Shao, Y., & Zhang, X. D. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1908-1 · Cited by 58 · see citing works
Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition
Bao, Y., Lu, Y., Wang, X., Feng, W., Sun, X., Guo, H., Tang, C., Zhang, X., Shi, Q., & Yu, H. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0250-9 · Cited by 56 · see citing works
Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?
da Fonseca, L. M., da Silva, V. A., Freire‐de‐Lima, L., Previato, J. O., Mendonça‐Previato, L., & Capella, M. A. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00158 · Cited by 56 · see citing works
pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression
Yin, J., Lang, T., Cun, D., Zheng, Z., Huang, Y. L., Yin, Q., Yu, H., & Li, Y. (2017) · Theranostics · doi:10.7150/thno.21516 · Cited by 56 · see citing works
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
Guo, W., Zhu, L., Yu, M., Zhu, R., Chen, Q., & Wang, Q. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0574-0 · Cited by 54 · see citing works
Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers
Zhang, J., & Huang, K. (2017) · BMC Genomics · doi:10.1186/s12864-016-3259-0 · Cited by 54 · see citing works
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Xiao, W., Zhou, Q., Wen, X., Wang, R., Liu, R., Wang, T., Shi, J., Hu, Y., & Hou, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702360 · Cited by 50 · see citing works
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
Zhao, H., Ning, S., Scicinski, J. J., Oronsky, B. T., Knox, S. J., & Peehl, D. M. (2015) · Oncotarget · doi:10.18632/oncotarget.6526 · Cited by 53 · see citing works
Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization
So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 53 · see citing works
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis
Curry, E. W., Zeller, C., Masrour, N., Patten, D. K., Gallon, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., Bowtell, D. D. L., & Brown, R. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1650 · Cited by 53 · see citing works
Self-citation
The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma
Wu, Q., Berglund, A., & Etame, A. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158324 · Cited by 50 · see citing works
H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape
Furth, N., Algranati, D., Dassa, B., Beresh, O., Fedyuk, V., Morris, N., Kasper, L. H., Jones, D. R., Monje, M., Baker, S. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110836 · Cited by 49 · see citing works
Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
Kagohara, L. T., Zamunér, F. T., Davis-Marcisak, E. F., Sharma, G., Considine, M., Allen, J., Yegnasubramanian, S., Gaykalova, D. A., & Fertig, E. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0851-5 · Cited by 50 · see citing works
Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution
Gupta, R. G., & Somer, R. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0070 · Cited by 48 · see citing works
Epigenome Remodeling in Cholangiocarcinoma
O’Rourke, C. J., Lafuente-Barquero, J. F., & Andersen, J. B. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.002 · Cited by 48 · see citing works
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells
Zhang, L., Lü, J., Liu, R., Hu, M., Zhao, Y., Tan, S. H., Wang, S.-Y., Zhang, B., Nie, W., Dong, Y., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0421-7 · Cited by 48 · see citing works
Slow-growing cells within isogenic populations have increased RNA polymerase error rates and DNA damage
van Dijk, D., Dhar, R., Missarova, A. M., Espinar, L., Blevins, W. R., Lehner, B., & Carey, L. B. (2015) · Nature Communications · doi:10.1038/ncomms8972 · Cited by 48 · see citing works
Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy
Yu, M., Liu, T., Chen, Y.-C., Li, Y., & Li, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0779-2 · Cited by 48 · see citing works
Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance
Ponnusamy, L., Mahalingaiah, P. K. S., & Singh, K. P. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.011 · Cited by 48 · see citing works
Glioblastoma Recurrence and the Role of O6-Methylguanine–DNA Methyltransferase Promoter Methylation
Storey, K. M., Leder, K., Hawkins-Daarud, A. J., Swanson, K. R., Ahmed, A. U., Rockne, R. C., & Foo, J. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00062 · Cited by 47 · see citing works
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park, J., Thomas, S., & Munster, P. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 49 · see citing works
Evolution of cancer cell populations under cytotoxic therapy and treatment optimisation: insight from a phenotype-structured model
de Almeida, L. N., Bagnerini, P., Fabrini, G., Hughes, B. D., & Lorenzi, T. (2019) · ESAIM Mathematical Modelling and Numerical Analysis · doi:10.1051/m2an/2019010 · Cited by 46 · see citing works
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
Shirbhate, E., Singh, V. P., Jahoriya, V., Mishra, A., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115938 · Cited by 45 · see citing works
Epigenetic drugs and their molecular targets in testicular germ cell tumours
Jostes, S., Nettersheim, D., & Schorle, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0154-x · Cited by 45 · see citing works
Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma
Wang, S., Cai, L., Zhang, F., Shang, X., Xiao, R., & Zhou, H. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.01.002 · Cited by 45 · see citing works
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Kusakabe, Y., Chiba, T., Oshima, M., Koide, S., Rizq, O., Aoyama, K., Ao, J., Kaneko, T., Kanzaki, H., Kanayama, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00889-0 · Cited by 45 · see citing works

Authors: Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J.
Affiliations: Hammersmith Hospital (GB)
Corresponding author: Brown, Robert
ORCID: Brown, Robert
Curry, Edward
Magnani, Luca
Wilhelm-Benartzi, Charlotte S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-09-25
Volume: 14
Issue: 11
Pages: 747-753
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3819
OpenAlex: W2095124748
Cited by: 301
References: 96
Citations by year: 2026: 4 · 2025: 16 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 41 · 2020: 37 · 2019: 34 · 2018: 27 · 2017: 23 · 2016: 30 · 2015: 18 · 2014: 1
FWCI: 2.29
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: Cancer Research UK (13086, A13086, 15954)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: epigenetic heterogeneity, acquired drug resistance, cancer, epigenetic targeting, chemoresistance, gene expression evolution
MeSH terms: Animals, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Poised epigenetic states and acquired drug resistance in cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks